Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality of Shigella-specific antibodies

Front Immunol. 2024 Apr 12:15:1374293. doi: 10.3389/fimmu.2024.1374293. eCollection 2024.

Abstract

Introduction: Shigella is the etiologic agent of a bacillary dysentery known as shigellosis, which causes millions of infections and thousands of deaths worldwide each year due to Shigella's unique lifestyle within intestinal epithelial cells. Cell adhesion/invasion assays have been extensively used not only to identify targets mediating host-pathogen interaction, but also to evaluate the ability of Shigella-specific antibodies to reduce virulence. However, these assays are time-consuming and labor-intensive and fail to assess differences at the single-cell level.

Objectives and methods: Here, we developed a simple, fast and high-content method named visual Adhesion/Invasion Inhibition Assay (vAIA) to measure the ability of anti-Shigellaantibodies to inhibit bacterial adhesion to and invasion of epithelial cells by using the confocal microscope Opera Phenix.

Results: We showed that vAIA performed well with a pooled human serum from subjects challenged with S. sonnei and that a specific anti-IpaD monoclonal antibody effectively reduced bacterial virulence in a dose-dependent manner.

Discussion: vAIA can therefore inform on the functionality of polyclonal and monoclonal responses thereby supporting the discovery of pathogenicity mechanisms and the development of candidate vaccines and immunotherapies. Lastly, this assay is very versatile and may be easily applied to other Shigella species or serotypes and to different pathogens.

Keywords: Shigella pathogenesis; antibodies; confocal microscopy; functional assay; inhibition of adhesion/invasion; single-cell high-content assay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial* / immunology
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Bacterial Adhesion* / immunology
  • Dysentery, Bacillary* / diagnosis
  • Dysentery, Bacillary* / immunology
  • Dysentery, Bacillary* / microbiology
  • Epithelial Cells / immunology
  • Epithelial Cells / microbiology
  • HeLa Cells
  • Host-Pathogen Interactions / immunology
  • Humans
  • Shigella / immunology
  • Shigella / pathogenicity
  • Shigella sonnei / immunology

Substances

  • Antibodies, Bacterial
  • Antibodies, Monoclonal

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Wellcome Trust through the ShiMabs grant “Human monoclonal antibodies against Shigella (ShiMabs), for therapy and vaccine acceleration” (219666/Z/19/Z).